Comparing a new drug to docetaxel for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug (7MW3711) against a standard chemotherapy (docetaxel) for people with advanced squamous non-small cell lung cancer that has progressed after prior chemo-immunotherapy. The goal is to see if the new drug is more effective or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of advanced lung cancer called squamous non-small cell lung cancer.
- Your cancer must have gotten worse after you received chemotherapy and an immunotherapy drug as your first treatment.
- Your tumor must not have certain gene changes like EGFR or ALK.
- You must be between 18 and 85 years old and generally able to care for yourself (ECOG 0-1).
- You must provide an archived sample of your tumor tissue.
- You must not have had an antibody-drug conjugate (ADC) or docetaxel before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
This study tests a new combination of drugs (HS-20093 plus adebrelimab) against a standard chemotherapy (docetaxel) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment. The goal is to see if the new combination is more effective and safer than the standard chemo.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This trial compares a new drug called SYS6010 to a standard chemotherapy drug (docetaxel) for people with advanced non-small cell lung cancer that has not responded to previous treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new Lung Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.